The present invention provides a process for the preparation of vigabatrin of formula (I) comprising of dissolving vigabatrin in water, optionally treating with charcoal, filtering and adding an acid to the reaction mass followed by the addition of an organic solvent and then isolating vigabatrin of formula (I) with high purity.

##STR00001##

Disclosed are catalysts comprised of platinum and gold. The catalysts are generally useful for the selective oxidation of compositions comprised of a primary alcohol group and at least one secondary alcohol group wherein at least the primary alcohol group is converted to a carboxyl group. More particularly, the catalysts are supported catalysts including particles comprising gold and particles comprising platinum, wherein the molar ratio of platinum to gold is in the range of about 100:1 to about 1:4, the platinum is essentially present as Pt(0) and the platinum-containing particles are of a size in the range of about 2 to about 50 nm. Also disclosed are methods for the oxidative chemocatalytic conversion of carbohydrates to carboxylic acids or derivatives thereof. Additionally, methods are disclosed for the selective oxidation of glucose to glucaric acid or derivatives thereof using catalysts comprising platinum and gold. Further, methods are disclosed for the production of such catalysts.

Disclosed are catalysts comprised of platinum and gold. The catalysts are generally useful for the selective oxidation of compositions comprised of a primary alcohol group and at least one secondary alcohol group wherein at least the primary alcohol group is converted to a carboxyl group. More particularly, the catalysts are supported catalysts including particles comprising gold and particles comprising platinum, wherein the molar ratio of platinum to gold is in the range of about 100:1 to about 1:4, the platinum is essentially present as Pt(0) and the platinum-containing particles are of a size in the range of about 2 to about 50 nm. Also disclosed are methods for the oxidative chemocatalytic conversion of carbohydrates to carboxylic acids or derivatives thereof. Additionally, methods are disclosed for the selective oxidation of glucose to glucaric acid or derivatives thereof using catalysts comprising platinum and gold. Further, methods are disclosed for the production of such catalysts.

Disclosed are catalysts comprised of platinum and gold. The catalysts are generally useful for the selective oxidation of compositions comprised of a primary alcohol group and at least one secondary alcohol group wherein at least the primary alcohol group is converted to a carboxyl group. More particularly, the catalysts are supported catalysts including particles comprising gold and particles comprising platinum, wherein the molar ratio of platinum to gold is in the range of about 100:1 to about 1:4, the platinum is essentially present as Pt(0) and the platinum-containing particles are of a size in the range of about 2 to about 50 nm. Also disclosed are methods for the oxidative chemocatalytic conversion of carbohydrates to carboxylic acids or derivatives thereof. Additionally, methods are disclosed for the selective oxidation of glucose to glucaric acid or derivatives thereof using catalysts comprising platinum and gold. Further, methods are disclosed for the production of such catalysts.

A process is provided for converting cyclic alkyleneureas into their corresponding alkyleneamines. The process includes reacting a feedstock comprising cyclic alkyleneureas in the liquid phase with water in an amount of from about 0.1 to about 20 mole water per mole urea moiety, at a temperature of at least 230 C., with removal of CO2. The process may allow the efficient conversion of alkyleneureas into the corresponding alkyleneamines. In certain embodiments, the process has a high yield and low side product production.

The present disclosure discloses a quantum dot and a preparation method thereof, the method comprises a plurality of following steps: preparing a quantum dot solution; preparing an ion-containing organic ligand precursor; adding the ion-containing organic ligand precursor into the quantum dot solution, and making a surface-modification to the quantum dots, before obtaining the quantum dots having the surfaces modified; or providing a quantum dot solution; providing an ion-containing organic ligand precursor; mixing the ion-containing organic ligand precursor and the quantum dot solution, to make a ligand exchanging, before centrifuging and obtaining the quantum dots having the ligand exchanged.

This disclosure relates to a method for treating a disease which can be alleviated by inhibiting PAICS activity. The method includes administering a therapeutically effective amount of spermine or a pharmaceutically acceptable salt or C.sub.1-C.sub.6 amide thereof to a patient in need thereof.

This disclosure relates to a method for treating a disease which can be alleviated by inhibiting PAICS activity. The method includes administering a therapeutically effective amount of spermine or a pharmaceutically acceptable salt or C.sub.1-C.sub.6 amide thereof to a patient in need thereof.

Disclosed is crystalline Form A of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d.sub.3)pyridazine-3-carboxamide. Form A is a neat crystalline form. Characterization data for Form A are disclosed.

Disclosed is crystalline Form A of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d.sub.3)pyridazine-3-carboxamide. Form A is a neat crystalline form. Characterization data for Form A are disclosed.